These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16515872)

  • 1. Lysosomal storage diseases: natural history and ethical and economic aspects.
    Beutler E
    Mol Genet Metab; 2006 Jul; 88(3):208-15. PubMed ID: 16515872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme reconstitution/replacement therapy for lysosomal storage diseases.
    Burrow TA; Hopkin RJ; Leslie ND; Tinkle BT; Grabowski GA
    Curr Opin Pediatr; 2007 Dec; 19(6):628-35. PubMed ID: 18025928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme Replacement Therapy for Lysosomal Storage Diseases.
    Kleppin S
    J Infus Nurs; 2020; 43(5):243-245. PubMed ID: 32881810
    [No Abstract]   [Full Text] [Related]  

  • 4. Treating lysosomal storage disorders: What have we learnt?
    Lachmann RH
    J Inherit Metab Dis; 2020 Jan; 43(1):125-132. PubMed ID: 31140601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roscoe Owen Brady, MD: Remembrances of co-investigators and colleagues.
    Desnick RJ; Barton NW; Furbish S; Grabowski GA; Karlsson S; Kolodny EH; Medin JA; Murray GJ; Mistry PK; Patterson MC; Schiffmann R; Weinreb NJ
    Mol Genet Metab; 2017; 120(1-2):1-7. PubMed ID: 27866832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment for LSDs: no longer just enzyme replacement therapy for Gaucher disease. Foreword.
    Cohen IJ; Baris H; Mistry PK
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():58. PubMed ID: 24380122
    [No Abstract]   [Full Text] [Related]  

  • 7. Alglucerase: the debate continues.
    Push S
    Pharmacoeconomics; 1995 Mar; 7(3):268-9. PubMed ID: 10155316
    [No Abstract]   [Full Text] [Related]  

  • 8. Delivery of lysosomal enzymes for therapeutic use: glucocerebrosidase as an example.
    Grabowski GA
    Expert Opin Drug Deliv; 2006 Nov; 3(6):771-82. PubMed ID: 17076599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of antibodies in enzyme treatments and therapeutic strategies.
    Bigger BW; Saif M; Linthorst GE
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):183-94. PubMed ID: 25987172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy for lysosomal storage disorders: successful transition from concept to clinical practice.
    Sly WS
    Mo Med; 2004; 101(2):100-4. PubMed ID: 15119106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost reduction in the treatment of Gaucher s disease].
    García Salom P; Acedo A
    Farm Hosp; 2007; 31(3):194-5. PubMed ID: 17941761
    [No Abstract]   [Full Text] [Related]  

  • 12. Gaucher disease, enzyme replacement therapy, and the Patient Assistance Program.
    Goldwater RS
    J Intraven Nurs; 1996; 19(2):83-8. PubMed ID: 8852168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness controversy.
    Cox TM
    Pharmacoeconomics; 1995 Jul; 8(1):82-3. PubMed ID: 10155604
    [No Abstract]   [Full Text] [Related]  

  • 14. [Enzyme replacement therapy for lysosomal storage disorders].
    Valayannopoulos V; Brassier A; Chabli A; Caillaud C; Lemoine M; Odent T; Arnoux JB; de Lonlay P
    Arch Pediatr; 2011 Oct; 18(10):1119-23. PubMed ID: 21873040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy for Gaucher disease: don't stop thinking about tomorrow.
    Sidransky E; LaMarca ME; Ginns EI
    Mol Genet Metab; 2007 Feb; 90(2):122-5. PubMed ID: 17084653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario.
    Clarke JT; Amato D; Deber RB
    CMAJ; 2001 Sep; 165(5):595-6. PubMed ID: 11563212
    [No Abstract]   [Full Text] [Related]  

  • 17. [Financing of enzyme treatment in Gaucher disease].
    Wisløff F
    Tidsskr Nor Laegeforen; 2003 Feb; 123(3):364. PubMed ID: 12640908
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of Gaucher disease in a post-communist transitional health care system: Croatian experience.
    Mrsić M; Stavljenić-Rukavina A; Fumić K; Labar B; Bogdanić V; Potocki K; Kardum-Skelin I; Rovers D
    Croat Med J; 2003 Oct; 44(5):606-9. PubMed ID: 14515422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.
    Moyses C
    Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):955-60. PubMed ID: 12803929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten plus one challenges in diseases of the lysosomal system.
    Grabowski GA; Whitley C
    Mol Genet Metab; 2017; 120(1-2):38-46. PubMed ID: 27923545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.